Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res

Retrieve available abstracts of 127 articles:
HTML format



Single Articles


    November 2022
  1. PHILIPPSON C, Larsen S, Simon S, Vandekerkhove C, et al
    Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry.
    Breast Cancer Res. 2022;24:83.
    PubMed     Abstract available


  2. BALLINGER TJ, Thompson WR, Guise TA
    The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health.
    Breast Cancer Res. 2022;24:84.
    PubMed     Abstract available


  3. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:82.
    PubMed    


  4. WU L, Ye W, Liu Y, Chen D, et al
    An integrated deep learning model for the prediction of pathological complete response to neoadjuvant chemotherapy with serial ultrasonography in breast cancer patients: a multicentre, retrospective study.
    Breast Cancer Res. 2022;24:81.
    PubMed     Abstract available


  5. BALLOT E, Galland L, Mananet H, Boidot R, et al
    Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    Breast Cancer Res. 2022;24:80.
    PubMed     Abstract available


  6. KOLYVAS EA, Caldas C, Kelly K, Ahmad SS, et al
    Androgen receptor function and targeted therapeutics across breast cancer subtypes.
    Breast Cancer Res. 2022;24:79.
    PubMed     Abstract available


  7. ASAD S, Damicis A, Heng YJ, Kananen K, et al
    Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses' health study.
    Breast Cancer Res. 2022;24:78.
    PubMed     Abstract available


  8. PEDERSEN DC, Jensen BW, Tjonneland A, Andersen ZJ, et al
    Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes.
    Breast Cancer Res. 2022;24:77.
    PubMed     Abstract available


  9. SZABOVA L, Gordon MB, Lu L, Pate N, et al
    Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.
    Breast Cancer Res. 2022;24:75.
    PubMed     Abstract available


  10. CRAGER M, Wijayawardana SR, Gruver AM, Blacklock A, et al
    Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score(R) result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer.
    Breast Cancer Res. 2022;24:74.
    PubMed     Abstract available


    October 2022
  11. HAN SJ, Sung N, Wang J, O'Malley BW, et al
    Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment.
    Breast Cancer Res. 2022;24:73.
    PubMed     Abstract available


  12. KARTHIKEYAN S, Casey PJ, Wang M
    RAB4A GTPase regulates epithelial-to-mesenchymal transition by modulating RAC1 activation.
    Breast Cancer Res. 2022;24:72.
    PubMed     Abstract available


  13. LA VERDE N, Damia G, Garrone O, Santini D, et al
    Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
    Breast Cancer Res. 2022;24:71.
    PubMed     Abstract available


  14. DU T, Pan L, Zheng C, Chen K, et al
    Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
    Breast Cancer Res. 2022;24:70.
    PubMed     Abstract available


  15. GIARDIELLO D, Hooning MJ, Hauptmann M, Keeman R, et al
    PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.
    Breast Cancer Res. 2022;24:69.
    PubMed     Abstract available


  16. ZHENG ZY, Elsarraj H, Lei JT, Hong Y, et al
    Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness.
    Breast Cancer Res. 2022;24:68.
    PubMed     Abstract available


  17. ONAGI H, Horimoto Y, Sakaguchi A, Ikarashi D, et al
    High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
    Breast Cancer Res. 2022;24:67.
    PubMed     Abstract available


  18. NOUNU A, Kar SP, Relton CL, Richmond RC, et al
    Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study.
    Breast Cancer Res. 2022;24:66.
    PubMed     Abstract available


  19. LUCHTENBORG AM, Metzger P, Cosenza Contreras M, Oria V, et al
    Kruppel-like factor 7 influences translation and pathways involved in ribosomal biogenesis in breast cancer.
    Breast Cancer Res. 2022;24:65.
    PubMed     Abstract available


    September 2022
  20. ZIOLKOWSKI P, Wozniak M, Mansour A, An Y, et al
    Breast cancer risk in papilloma patients: Osteopontin splice variants indicate prognosis.
    Breast Cancer Res. 2022;24:64.
    PubMed     Abstract available


  21. DENG N, Minoche A, Harvey K, Li M, et al
    Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models.
    Breast Cancer Res. 2022;24:63.
    PubMed     Abstract available


  22. LOPEZ-KNOWLES E, Detre S, Hills M, Schuster EF, et al
    Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
    Breast Cancer Res. 2022;24:61.
    PubMed     Abstract available


  23. LI C, Yoshimura T, Tian M, Wang Y, et al
    Exosomal Wnt7a from a low metastatic subclone promotes lung metastasis of a highly metastatic subclone in the murine 4t1 breast cancer.
    Breast Cancer Res. 2022;24:60.
    PubMed     Abstract available


  24. LOUDIG O, Mitchell MI, Ben-Dov IZ, Liu C, et al
    MiRNA expression deregulation correlates with the Oncotype DX((R)) DCIS score.
    Breast Cancer Res. 2022;24:62.
    PubMed     Abstract available


  25. DUGUE PA, Bodelon C, Chung FF, Brewer HR, et al
    Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.
    Breast Cancer Res. 2022;24:59.
    PubMed     Abstract available


  26. KOLBERG-LIEDTKE C, Feuerhake F, Garke M, Christgen M, et al
    Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Breast Cancer Res. 2022;24:58.
    PubMed     Abstract available


    August 2022
  27. LIU C, Hu S, Xu X, Zhang Y, et al
    Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment.
    Breast Cancer Res. 2022;24:57.
    PubMed     Abstract available


  28. CLARKE S, Chin SN, Dodds L, George SHL, et al
    Racial disparities in breast cancer preclinical and clinical models.
    Breast Cancer Res. 2022;24:56.
    PubMed     Abstract available


    July 2022
  29. JONES LI, Marshall A, Elangovan P, Geach R, et al
    Evaluating the effectiveness of abbreviated breast MRI (abMRI) interpretation training for mammogram readers: a multi-centre study assessing diagnostic performance, using an enriched dataset.
    Breast Cancer Res. 2022;24:55.
    PubMed     Abstract available


  30. LEE S, Osmanbeyoglu HU
    Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.
    Breast Cancer Res. 2022;24:54.
    PubMed     Abstract available


  31. PAPADAKI C, Stratigos M, Markakis G, Spiliotaki M, et al
    Correction to: Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
    Breast Cancer Res. 2022;24:53.
    PubMed    


  32. HANNA A, Nixon MJ, Estrada MV, Sanchez V, et al
    Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer.
    Breast Cancer Res. 2022;24:51.
    PubMed     Abstract available


  33. SALVATI A, Melone V, Sellitto A, Rizzo F, et al
    Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
    Breast Cancer Res. 2022;24:52.
    PubMed     Abstract available


  34. VAN GEELEN CT, Savas P, Teo ZL, Luen SJ, et al
    Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    Breast Cancer Res. 2022;24:50.
    PubMed    


  35. WARD SV, Burton A, Tamimi RM, Pereira A, et al
    The association of age at menarche and adult height with mammographic density in the International Consortium of Mammographic Density.
    Breast Cancer Res. 2022;24:49.
    PubMed     Abstract available


  36. MIR S, Golden BDO, Griess BJ, Vengoji R, et al
    Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.
    Breast Cancer Res. 2022;24:48.
    PubMed     Abstract available


  37. AL-TWEIGERI T, AlRaouji NN, Tulbah A, Arafah M, et al
    High AUF1 level in stromal fibroblasts promotes carcinogenesis and chemoresistance and predicts unfavorable prognosis among locally advanced breast cancer patients.
    Breast Cancer Res. 2022;24:46.
    PubMed     Abstract available


  38. KEHM RD, Walter EJ, Oskar S, White ML, et al
    Exposure to polycyclic aromatic hydrocarbons during pregnancy and breast tissue composition in adolescent daughters and their mothers: a prospective cohort study.
    Breast Cancer Res. 2022;24:47.
    PubMed     Abstract available


  39. OGONY J, de Bel T, Radisky DC, Kachergus J, et al
    Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence.
    Breast Cancer Res. 2022;24:45.
    PubMed     Abstract available


    June 2022
  40. WAGNER KU
    Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors.
    Breast Cancer Res. 2022;24:44.
    PubMed    


  41. PEDERSEN CA, Cao MD, Fleischer T, Rye MB, et al
    DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival.
    Breast Cancer Res. 2022;24:43.
    PubMed     Abstract available


  42. WELLBERG EA, Corleto KA, Checkley LA, Jindal S, et al
    Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer.
    Breast Cancer Res. 2022;24:42.
    PubMed     Abstract available


  43. RATZ L, Brambillasca C, Bartke L, Huetzen MA, et al
    Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    Breast Cancer Res. 2022;24:41.
    PubMed     Abstract available


  44. CARR D, Zein A, Coulombe J, Jiang T, et al
    Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.
    Breast Cancer Res. 2022;24:40.
    PubMed     Abstract available


  45. ONG CHC, Lee DY, Lee B, Li H, et al
    Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
    Breast Cancer Res. 2022;24:38.
    PubMed     Abstract available


  46. HARRASSER M, Gohil SH, Lau H, Della Peruta M, et al
    Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Breast Cancer Res. 2022;24:39.
    PubMed     Abstract available


  47. SIEGEL SD, Brooks MM, Lynch SM, Sims-Mourtada J, et al
    Racial disparities in triple negative breast cancer: toward a causal architecture approach.
    Breast Cancer Res. 2022;24:37.
    PubMed     Abstract available


    May 2022
  48. KOEVOETS EW, Schagen SB, de Ruiter MB, Geerlings MI, et al
    Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study).
    Breast Cancer Res. 2022;24:36.
    PubMed     Abstract available


  49. RAGHAVAKAIMAL A, Cristofanilli M, Tang CM, Alpaugh RK, et al
    CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome.
    Breast Cancer Res. 2022;24:35.
    PubMed     Abstract available


  50. RALLI GP, Carter RD, McGowan DR, Cheng WC, et al
    Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.
    Breast Cancer Res. 2022;24:34.
    PubMed     Abstract available


  51. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
    Infertility and risk of breast cancer in men: a national case-control study in England and Wales.
    Breast Cancer Res. 2022;24:29.
    PubMed     Abstract available


  52. ROUSSEAU B, Murugan S, Palagani A, Sarkar DK, et al
    Beta 2 adrenergic receptor and mu opioid receptor interact to potentiate the aggressiveness of human breast cancer cell by activating the glycogen synthase kinase 3 signaling.
    Breast Cancer Res. 2022;24:33.
    PubMed     Abstract available


  53. ZHENG J, Zhang B
    Biological interpretation of prognostic radiomic score by correlating with tumor heterogeneity and microenvironment.
    Breast Cancer Res. 2022;24:32.
    PubMed    


  54. HO WJ, Law AMK, Masle-Farquhar E, Castillo LE, et al
    Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases.
    Breast Cancer Res. 2022;24:31.
    PubMed     Abstract available


    April 2022
  55. GRINMAN DY, Boras-Granic K, Takyar FM, Dann P, et al
    PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.
    Breast Cancer Res. 2022;24:30.
    PubMed     Abstract available


  56. MINTZ R, Wang M, Xu S, Colditz GA, et al
    Hormone and receptor activator of NF-kappaB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women.
    Breast Cancer Res. 2022;24:28.
    PubMed     Abstract available


  57. CHEN H, Fan S, Stone J, Thompson DJ, et al
    Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci.
    Breast Cancer Res. 2022;24:27.
    PubMed     Abstract available


  58. LIU Z, Liu J, Ebrahimi B, Pratap UP, et al
    SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Breast Cancer Res. 2022;24:26.
    PubMed     Abstract available


  59. FOO SL, Sachaphibulkij K, Lee CLY, Yap GLR, et al
    Breast cancer metastasis to brain results in recruitment and activation of microglia through annexin-A1/formyl peptide receptor signaling.
    Breast Cancer Res. 2022;24:25.
    PubMed     Abstract available


  60. RENAULT AL, Dowty JG, Steen JA, Li S, et al
    Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
    Breast Cancer Res. 2022;24:24.
    PubMed     Abstract available


  61. HEYNEN GJJE, Lisek K, Vogel R, Wulf-Goldenberg A, et al
    Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors.
    Breast Cancer Res. 2022;24:23.
    PubMed     Abstract available


    March 2022
  62. WON HS, Ahn J, Kim Y, Kim JS, et al
    Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res. 2022;24:22.
    PubMed     Abstract available


  63. TU CF, Li FA, Li LH, Yang RB, et al
    Quantitative glycoproteomics analysis identifies novel FUT8 targets and signaling networks critical for breast cancer cell invasiveness.
    Breast Cancer Res. 2022;24:21.
    PubMed     Abstract available


  64. WANG X, Xie T, Luo J, Zhou Z, et al
    Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment.
    Breast Cancer Res. 2022;24:20.
    PubMed     Abstract available


  65. SEMINA SE, Pal P, Kansara NS, Huggins RJ, et al
    Selective pressure of endocrine therapy activates the integrated stress response through NFkappaB signaling in a subpopulation of ER positive breast cancer cells.
    Breast Cancer Res. 2022;24:19.
    PubMed     Abstract available


  66. LIU M, Smith R, Liby T, Chiotti K, et al
    INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.
    Breast Cancer Res. 2022;24:18.
    PubMed     Abstract available


  67. WATT AC, Goel S
    Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer.
    Breast Cancer Res. 2022;24:17.
    PubMed     Abstract available


  68. GU J, Ternifi R, Larson NB, Carter JM, et al
    Hybrid high-definition microvessel imaging/shear wave elastography improves breast lesion characterization.
    Breast Cancer Res. 2022;24:16.
    PubMed     Abstract available


    February 2022
  69. SYRIOPOULOU E, Gasparini A, Humphreys K, Andersson TM, et al
    Assessing lead time bias due to mammography screening on estimates of loss in life expectancy.
    Breast Cancer Res. 2022;24:15.
    PubMed     Abstract available


  70. GASTOUNIOTI A, Desai S, Ahluwalia VS, Conant EF, et al
    Artificial intelligence in mammographic phenotyping of breast cancer risk: a narrative review.
    Breast Cancer Res. 2022;24:14.
    PubMed     Abstract available


  71. THOMPSON KN, Ju JA, Ory EC, Pratt SJP, et al
    Microtubule disruption reduces metastasis more effectively than primary tumor growth.
    Breast Cancer Res. 2022;24:13.
    PubMed     Abstract available


  72. SUN L, Ding H, Jia Y, Shi M, et al
    Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Breast Cancer Res. 2022;24:12.
    PubMed     Abstract available


  73. WEI G, Teng M, Rosa M, Wang X, et al
    Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Breast Cancer Res. 2022;24:11.
    PubMed     Abstract available


    January 2022
  74. REN Q, Khoo WH, Corr AP, Phan TG, et al
    Gene expression predicts dormant metastatic breast cancer cell phenotype.
    Breast Cancer Res. 2022;24:10.
    PubMed     Abstract available


  75. GECZIK AM, Falk RT, Xu X, Ansong D, et al
    Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study.
    Breast Cancer Res. 2022;24:9.
    PubMed     Abstract available


  76. TANG YH, Rockstroh A, Sokolowski KA, Lynam LR, et al
    Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
    Breast Cancer Res. 2022;24:8.
    PubMed     Abstract available


  77. YIN L, Li Q, Mrdenovic S, Chu GC, et al
    KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway.
    Breast Cancer Res. 2022;24:7.
    PubMed     Abstract available


  78. DESHPANDE RP, Sharma S, Liu Y, Pandey PR, et al
    LncRNA IPW inhibits growth of ductal carcinoma in situ by downregulating ID2 through miR-29c.
    Breast Cancer Res. 2022;24:6.
    PubMed     Abstract available


  79. PIRIKAHU S, Lund H, Cadby G, Wylie E, et al
    The impact of breast density notification on rescreening rates within a population-based mammographic screening program.
    Breast Cancer Res. 2022;24:5.
    PubMed     Abstract available


  80. HJERKIND KV, Johansson ALV, Trewin CB, Russnes HG, et al
    Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway.
    Breast Cancer Res. 2022;24:4.
    PubMed     Abstract available


  81. YOON L, Corvalan C, Pereira A, Shepherd J, et al
    Sugar-sweetened beverage consumption and breast composition in a longitudinal study of Chilean girls.
    Breast Cancer Res. 2022;24:3.
    PubMed     Abstract available


  82. MENG L, Chang S, Sang Y, Ding P, et al
    Circular RNA circCCDC85A inhibits breast cancer progression via acting as a miR-550a-5p sponge to enhance MOB1A expression.
    Breast Cancer Res. 2022;24:1.
    PubMed     Abstract available


  83. AHEARN TU, Zhang H, Michailidou K, Milne RL, et al
    Common variants in breast cancer risk loci predispose to distinct tumor subtypes.
    Breast Cancer Res. 2022;24:2.
    PubMed     Abstract available


    December 2021
  84. NIWINSKA A, Olszewski WP
    The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
    Breast Cancer Res. 2021;23:118.
    PubMed     Abstract available


  85. SANDSVEDEN M, Borgquist S, Rosendahl AH, Manjer J, et al
    Low thyroid hormone receptor alpha-2 (THRalpha-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality.
    Breast Cancer Res. 2021;23:117.
    PubMed     Abstract available


  86. CHEUNG AM, Wang D, Liu K, Hope T, et al
    Quantitative single-cell analysis of immunofluorescence protein multiplex images illustrates biomarker spatial heterogeneity within breast cancer subtypes.
    Breast Cancer Res. 2021;23:114.
    PubMed     Abstract available


  87. ZHANG M, Meng M, Liu Y, Qi J, et al
    Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins.
    Breast Cancer Res. 2021;23:116.
    PubMed     Abstract available


  88. LIU S, Chen W, Hu H, Zhang T, et al
    Long noncoding RNA PVT1 promotes breast cancer proliferation and metastasis by binding miR-128-3p and UPF1.
    Breast Cancer Res. 2021;23:115.
    PubMed     Abstract available


  89. YAGHOOBI V, Moutafi M, Aung TN, Pelekanou V, et al
    Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.
    Breast Cancer Res. 2021;23:113.
    PubMed     Abstract available


  90. GAMPENRIEDER SP, Rinnerthaler G, Tinchon C, Petzer A, et al
    Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
    Breast Cancer Res. 2021;23:112.
    PubMed     Abstract available


  91. GOLDBERG M, D'Aloisio AA, O'Brien KM, Zhao S, et al
    Early-life exposures and age at thelarche in the Sister Study cohort.
    Breast Cancer Res. 2021;23:111.
    PubMed     Abstract available


    November 2021
  92. VIROSTKO J, Sorace AG, Slavkova KP, Kazerouni AS, et al
    Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting.
    Breast Cancer Res. 2021;23:110.
    PubMed     Abstract available


  93. BOUCHERON P, Anele A, Zietsman A, Galukande M, et al
    Self-reported arm and shoulder problems in breast cancer survivors in Sub-Saharan Africa: the African Breast Cancer-Disparities in Outcomes cohort study.
    Breast Cancer Res. 2021;23:109.
    PubMed     Abstract available


  94. LABRECHE C, Cook DP, Abou-Hamad J, Pascoal J, et al
    Periostin gene expression in neu-positive breast cancer cells is regulated by a FGFR signaling cross talk with TGFbeta/PI3K/AKT pathways.
    Breast Cancer Res. 2021;23:107.
    PubMed     Abstract available


  95. BARBER LE, Zirpoli GR, Cozier YC, Rosenberg L, et al
    Neighborhood disadvantage and individual-level life stressors in relation to breast cancer incidence in US Black women.
    Breast Cancer Res. 2021;23:108.
    PubMed     Abstract available


  96. LIU FC, Veierod MB, Kjaerheim K, Robsahm TE, et al
    Excess risk of male breast cancer in the Norwegian Offshore Petroleum Workers (NOPW) cohort: a possible link to extreme night shift work?
    Breast Cancer Res. 2021;23:106.
    PubMed    


  97. BODELON C, Mullooly M, Pfeiffer RM, Fan S, et al
    Mammary collagen architecture and its association with mammographic density and lesion severity among women undergoing image-guided breast biopsy.
    Breast Cancer Res. 2021;23:105.
    PubMed     Abstract available


  98. JESSER EA, Brady NJ, Huggins DN, Witschen PM, et al
    STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment.
    Breast Cancer Res. 2021;23:104.
    PubMed     Abstract available


  99. HANAMURA T, Christenson JL, O'Neill KI, Rosas E, et al
    Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
    Breast Cancer Res. 2021;23:102.
    PubMed     Abstract available


  100. COLLIN LJ, Maliniak ML, Cronin-Fenton DP, Ahern TP, et al
    Hypoxia-inducible factor-1alpha expression and breast cancer recurrence in a Danish population-based case control study.
    Breast Cancer Res. 2021;23:103.
    PubMed     Abstract available


    October 2021
  101. ROPRI AS, DeVaux RS, Eng J, Chittur SV, et al
    Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Breast Cancer Res. 2021;23:101.
    PubMed     Abstract available


  102. SCHERER SD, Riggio AI, Haroun F, DeRose YS, et al
    An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer.
    Breast Cancer Res. 2021;23:100.
    PubMed     Abstract available


  103. SAKAGUCHI A, Horimoto Y, Onagi H, Ikarashi D, et al
    Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res. 2021;23:99.
    PubMed     Abstract available


  104. FUH KF, Shepherd RD, Withell JS, Kooistra BK, et al
    Fluid flow exposure promotes epithelial-to-mesenchymal transition and adhesion of breast cancer cells to endothelial cells.
    Breast Cancer Res. 2021;23:97.
    PubMed     Abstract available


  105. CHEN X, Chen DG, Zhao Z, Balko JM, et al
    Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms.
    Breast Cancer Res. 2021;23:96.
    PubMed     Abstract available


  106. HAZLETT J, Niemi V, Aiderus A, Powell K, et al
    Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer.
    Breast Cancer Res. 2021;23:95.
    PubMed     Abstract available


    September 2021
  107. LIOU L, Kaptoge S, Dennis J, Shah M, et al
    Genomic risk prediction of coronary artery disease in women with breast cancer: a prospective cohort study.
    Breast Cancer Res. 2021;23:94.
    PubMed     Abstract available


  108. LEOCE NM, Jin Z, Kehm RD, Roh JM, et al
    Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer.
    Breast Cancer Res. 2021;23:91.
    PubMed     Abstract available


  109. IONKINA AA, Balderrama-Gutierrez G, Ibanez KJ, Phan SHD, et al
    Transcriptome analysis of heterogeneity in mouse model of metastatic breast cancer.
    Breast Cancer Res. 2021;23:93.
    PubMed     Abstract available


  110. ZARE A, Postovit LM, Githaka JM
    Robust inflammatory breast cancer gene signature using nonparametric random forest analysis.
    Breast Cancer Res. 2021;23:92.
    PubMed     Abstract available


  111. IBRAHIM AM, Bilsland A, Rickelt S, Morris JS, et al
    A matrisome RNA signature from early-pregnancy mouse mammary fibroblasts predicts distant metastasis-free breast cancer survival in humans.
    Breast Cancer Res. 2021;23:90.
    PubMed     Abstract available


  112. YANG L, Wang B, Jiao X, Zhou C, et al
    TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
    Breast Cancer Res. 2021;23:89.
    PubMed     Abstract available


    July 2021
  113. HIS M, Lajous M, Gomez-Flores-Ramos L, Monge A, et al
    Biomarkers of mammographic density in premenopausal women.
    Breast Cancer Res. 2021;23:75.
    PubMed     Abstract available


  114. LU P, Foley J, Zhu C, McNamara K, et al
    Transcriptome and genome evolution during HER2-amplified breast neoplasia.
    Breast Cancer Res. 2021;23:73.
    PubMed     Abstract available


  115. GARZIA NA, Cushing-Haugen K, Kensler TW, Tamimi RM, et al
    Adolescent and early adulthood inflammation-associated dietary patterns in relation to premenopausal mammographic density.
    Breast Cancer Res. 2021;23:71.
    PubMed     Abstract available


    June 2021
  116. RUTH JR, Pant DK, Pan TC, Seidel HE, et al
    Cellular dormancy in minimal residual disease following targeted therapy.
    Breast Cancer Res. 2021;23:63.
    PubMed     Abstract available


    May 2021
  117. SARRADIN V, Lusque A, Filleron T, Dalenc F, et al
    Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
    Breast Cancer Res. 2021;23:61.
    PubMed     Abstract available


  118. DE BOER LL, Kho E, Van de Vijver KK, Vranken Peeters MTFD, et al
    Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance.
    Breast Cancer Res. 2021;23:59.
    PubMed     Abstract available


  119. CONG L, Maishi N, Annan DA, Young MF, et al
    Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
    Breast Cancer Res. 2021;23:51.
    PubMed     Abstract available


    April 2021
  120. REIMERS LL, Goldberg M, Tehranifar P, Michels KB, et al
    Benign breast disease and changes in mammographic breast density.
    Breast Cancer Res. 2021;23:49.
    PubMed     Abstract available


  121. YANG HY, Tu CW, Chen CC, Lee CY, et al
    Sole adjuvant intraoperative breast radiotherapy in Taiwan: a single-center experience.
    Breast Cancer Res. 2021;23:43.
    PubMed     Abstract available


    February 2021
  122. SZUCS Z, Joseph J, Larkin TJ, Xie B, et al
    Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent.
    Breast Cancer Res. 2021;23:25.
    PubMed     Abstract available


  123. TIAN J, Wang V, Wang N, Khadang B, et al
    Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition.
    Breast Cancer Res. 2021;23:23.
    PubMed     Abstract available


    January 2021
  124. ALTOE ML, Kalinsky K, Marone A, Kim HK, et al
    Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.
    Breast Cancer Res. 2021;23:16.
    PubMed     Abstract available


  125. BAI F, Liu S, Liu X, Hollern DP, et al
    PDGFRbeta is an essential therapeutic target for BRCA1-deficient mammary tumors.
    Breast Cancer Res. 2021;23:10.
    PubMed     Abstract available


  126. RIEDLINGER GM, Joshi S, Hirshfield KM, Barnard N, et al
    Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
    Breast Cancer Res. 2021;23:7.
    PubMed     Abstract available


  127. MCCART REED AE, Kalinowski L, Simpson PT, Lakhani SR, et al
    Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
    Breast Cancer Res. 2021;23:6.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: